Related Experiment Video

Updated: Nov 18, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

396

Impact of hyperthyroidism on in-hospital outcomes of patients with heart failure

Kunjan Udani1, Dveet Patel1, Leslie Hart2

  • 1Department of Internal Medicine, Grand Strand Medical Center, Myrtle Beach, SC, USA.

Journal of Community Hospital Internal Medicine Perspectives
|February 8, 2021
PubMed

Insights

Hyperthyroidism (HT) does not significantly impact mortality or length of stay for congestive heart failure (CHF) patients. However, HT patients were younger females and had longer hospital stays if cardiovascular comorbidities were present.

Area of Science:

  • Cardiology
  • Endocrinology

Background:

  • Congestive heart failure (CHF) exacerbations are a leading cause of hospitalizations.
  • Thyroid hormones significantly influence myocardial function.
  • Hyperthyroidism (HT) can exacerbate CHF symptoms due to elevated thyroxine levels.

Purpose of the Study:

  • To evaluate the association between hyperthyroidism (HT) and outcomes in patients hospitalized with congestive heart failure (CHF).
  • To examine the impact of HT on mortality and length of stay (LOS) in CHF patients.

Main Methods:

  • Retrospective analysis of the Hospital Corporation of America (HCA) Enterprise Data Warehouse.
  • Inclusion of 55,031 patients diagnosed with CHF.
  • Comparison of mortality and LOS between CHF patients with and without a diagnosis of HT.

Main Results:

  • Hyperthyroidism (HT) was not significantly associated with increased mortality (p = 0.24) or length of stay (LOS) (p = 0.32) in CHF patients.
  • A significant difference in sex and age distribution was observed: CHF patients with HT were more often female and younger (p < 0.01).
  • Patients with CHF and HT exhibited a significantly longer mean LOS (6.33 days) compared to those without HT (5.31 days) when cardiovascular comorbidities were present (p = 0.04).

Conclusions:

  • Hyperthyroidism (HT) does not appear to be an independent predictor of mortality or prolonged LOS in hospitalized congestive heart failure (CHF) patients.
  • Demographic differences, specifically younger age and higher female prevalence, characterize CHF patients with HT.
  • The presence of cardiovascular comorbidities significantly impacts LOS in CHF patients with HT, suggesting complex interactions requiring further investigation.

Keywords:
Heart failureclinical decision makingclinical researchhyperthyroidismlength of staymortality

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.0K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
257
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
245
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.2K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
931
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
557
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
107